PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation.

Theman TA, Collins MT, Dempster DW, Zhou H, Reynolds JC, Brahim JS, Roschger P, Klaushofer K, Winer KK

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 May 2009Cited by 52 (Europe PMC)

PMID19063686PMCIDPMC2672210DOI10.1359/jbmr.081233PepBankPUB-19063686

Source link PubMedAsk about this study

Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

9 results from studies that gave the peptide. 9 results from people.

01HumanCase report or seriesEfficacy outcome
In the patient and ADH controls after PTH treatment, cancellous bone volume was dramatically elevated.
In plain wordsIn the patient and ADH controls receiving PTH, spongy bone volume was markedly elevated.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous bone volume
Study
n = 3
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Cancellous bone volume was dramatically elevated in the patient and in ADH controls after 1 yr of PTH.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368606
02HumanCase report or seriesActivity measurement
In ADH controls, mineralization decreased further after 1 yr of PTH compared with before treatment.
In plain wordsIn ADH controls, bone mineralization decreased after 1 yr of PTH compared with before treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseMineralization change in ADH controls
Study
n = 2
Comparator
Before PTH
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
Moreover, the ADH controls exhibited a further reduction in mineralization after 1 yr of PTH.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368608
03HumanCase report or seriesEfficacy outcome
In a patient with ADH receiving long-term PTH replacement, growth was normal.
In plain wordsIn a patient with ADH receiving long-term PTH, growth was normal.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableGrowth
Study
n = 1
Outcome group
Linear growth · Whole body
Studied dose
Dose not stated
Source sentences
Summary
The patient's growth was normal.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368601
04HumanCase report or seriesSafety outcome
In a patient with ADH receiving PTH, hypercalciuria persisted despite normal or subnormal serum calcium.
In plain wordsIn a patient with ADH receiving PTH, excessive urinary calcium persisted despite normal or low blood calcium.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableHypercalciuria
Study
n = 1
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Hypercalciuria and hypermagnesuria persisted despite normal or subnormal serum calcium and magnesium levels.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368602
05HumanCase report or seriesSafety outcome
In a patient with ADH receiving PTH, hypermagnesuria persisted despite normal or subnormal serum magnesium.
In plain wordsIn a patient with ADH receiving PTH, excessive urinary magnesium persisted despite normal or low blood magnesium.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableHypermagnesuria
Study
n = 1
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Hypercalciuria and hypermagnesuria persisted despite normal or subnormal serum calcium and magnesium levels.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368603
06HumanCase report or seriesSafety outcome
In a patient with ADH receiving long-term PTH, nephrocalcinosis developed by 19 yr of age.
In plain wordsIn a patient with ADH receiving PTH, calcium deposits developed in the kidneys by 19 yr of age.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableNephrocalcinosis
Study
n = 1
Outcome group
Adverse events · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Nephrocalcinosis, without evidence of impaired renal function, developed by 19 yr of age.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368604
07HumanCase report or seriesSafety outcome
In a patient with ADH receiving long-term PTH, nephrocalcinosis occurred without evidence of impaired renal function.
In plain wordsIn a patient with ADH receiving PTH, kidney calcium deposits occurred without evidence of impaired kidney function.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableRenal function
Study
n = 1
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Nephrocalcinosis, without evidence of impaired renal function, developed by 19 yr of age.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368605
08HumanCase report or seriesSafety outcome
In the patient receiving long-term PTH for ADH, no fractures were reported.
In plain wordsIn the patient receiving long-term PTH for ADH, no fractures were reported.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableFractures
Study
n = 1
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
There were no fractures or osteosarcoma.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368609
09HumanCase report or seriesSafety outcome
In the patient receiving long-term PTH for ADH, no osteosarcoma was reported.
In plain wordsIn the patient receiving long-term PTH for ADH, no bone cancer of the osteosarcoma type was reported.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableOsteosarcoma
Study
n = 1
Outcome group
Adverse events · Cancer
Studied dose
Dose not stated
Source sentences
Summary
There were no fractures or osteosarcoma.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
Report a problemFND-1906368610

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

10HumanNot a test of Teriparatide (PTH 1-34) aloneCase report or seriesActivity measurement
In the patient and ADH controls, bone mineralization distribution shifted lower than in the non-ADH control.
In plain wordsIn the patient and ADH controls, bone mineralization was lower than in the non-ADH control.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBone mineralization distribution
Study
n = 4
Comparator
Non-ADH control
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
BMD distribution (BMDD) by qBEI of the patient and ADH controls was strikingly shifted toward lower mineralization compared with the non-ADH control.
2 context sentences(design, population, supporting numbers)
Summary · context
The patient is a 20-yr-old female with ADH treated with PTH continuously since 6 yr and 2 mo of age.
Summary · context
Her data were compared with one age-, sex-, and length of hypoparathyroidism-matched control not on PTH and two sex-matched ADH controls before and after 1 yr of PTH.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1906368607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.